Doer Biologics
Chemicals & Related Products · United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
United StatesWebsite
www.doerbio.comRevenue
$11.1 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
1
1
1
1
1
About Doer Biologics
浙江道尔生物科技有限公司, established in April 2014, is a high-tech enterprise specializing in the development of innovative biopharmaceuticals under the East China Pharmaceutical Group. The company focuses on advanced technology platforms such as xLONGylation, MultipleBody, and AccuBody for precision cancer treatment. Their intended clients include healthcare providers and research institutions looking for cutting-edge biopharmaceutical solutions. The company has been recognized as a quasi-unicorn in Hangzhou for six consecutive years.Explore more
Doer Biologics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Doer Biologics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if Doer Biologics had a recent Job posting/layoffs
Earning: See what the market has to say on Doer Biologics recently announced quarterly report
Funding: Get notified immidiatlly once Doer Biologics has new funding data
Doer Biologics, which may be a good buyer, showed buying intent in Masked Content Topic
Check out if Doer Biologics is spiking on competitors!
Congratulate Masked Content for being promoted to Masked Content at Doer Biologics
Check if Doer Biologics has recently received funding, and reach out quickly before it becomes old news!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Product Launch: Get notified when Doer Biologics launches new products
Website visits: Recent activity has been detected on your website
Recommended Actions
Reach out to Masked Content who joined Doer Biologics as Masked Content
Find 3 more new buyers
Compare Similar Companies to Doer Biologics
Compare insights from companies similar to Doer Biologics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Doer Biologics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Doer Biologics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Doer Biologics.
Doer Biologics Tech Stack
A closer look at the technologies used by Doer Biologics
See more technologies
Doer Biologics News & Media
Doer Biologics Completes Enrollment of the Phase 2 Clinical Study of DR10624 for Treatment of Severe Hypertriglyceridemia
HANGZHOU, China, March 9, 2025 /PRNewswire/ -- Zhejiang Doer Biologics Co., Ltd. ("Doer Bio"), a clinical stage biopharmaceutical company developing innovative biotherapeutics for metabolic diseases and cancers, today announces that DR10624, its first-in-class (FIC), tri-specific agonist...Doer Biologics Announces First Patient Dosed in Phase 2 Study of DR10624 for Treatment of Severe Hypertriglyceridemia
HANGZHOU, China, Sept. 30, 2024 /PRNewswire/ -- Zhejiang Doer Biologics Co., Ltd. ("Doer Bio"), a clinical stage biopharmaceutical company developing innovative biotherapeutics for metabolic diseases and cancers, today announces that DR10624, its first-in-class (FIC), tri-specific agonist...Zhejiang Doer Biologics Completes Enrollment of the Phase 1b/2a Trial Evaluating DR10624 in Obese Subjects with Modest Hypertriglyceridemia
HANGZHOU, China, July 5, 2024 /PRNewswire/ -- Zhejiang Doer Biologics Co., Ltd. ("Doer Bio"), a clinical stage biopharmaceutical company developing innovative biotherapeutics for metabolic diseases and cancers, today announces that the company has completed the enrollment in the Phase 1b/2a trial evaluating DR10624 in obese subjects with modest hypertriglyceridemia in New Zealand. DR10624 is a first-in-class (FIC), long-acting tri-specific agonist targeting Fibroblast growth factor 21 receptor (Doer Biologics Announces First Subject Dosed in Phase I 12-Week Multiple-Ascending Dose (MAD) Clinical Trial of DR10624 and Received IND Approval From NMPA
HANGZHOU, China, Aug. 1, 2023 /PRNewswire/ -- Zhejiang Doer Biologics Co., Ltd. ("Doer Bio"), a clinical stage biopharmaceutical company developing innovative biotherapeutics for metabolic diseases and cancers, today announces that DR10624, its first-in-class (FIC), tri-specific agonist...
Read more news
Top Chemicals & Related Products Companies
See more top companies
Frequently Asked Questions Regarding Doer Biologics
Sign Up For FreeTo access detailed company insights
浙江道尔生物科技有限公司, established in April 2014, is a high-tech enterprise specializing in the development of innovative biopharmaceuticals under the East China Pharmaceutical Group. The company focuses on advanced technology platforms such as xLONGylation, MultipleBody, and AccuBody for precision cancer treatment. Their intended clients include healthcare... Read More
